A multi-centre, randomised, double-blind, placebo-controlled, dose ranging study to evaluate the safety and efficacy of GSK2586184 in patients with chronic plaque psoriasis

Trial Profile

A multi-centre, randomised, double-blind, placebo-controlled, dose ranging study to evaluate the safety and efficacy of GSK2586184 in patients with chronic plaque psoriasis

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs Solcitinib (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 19 Jan 2016 Results published in the British Journal of Dermatology
    • 30 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 17 Apr 2014 Preliminary results reported in a Galapagos media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top